271. 強直性脊椎炎 Ankylosing spondylitis Clinical trials / Disease details
臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2200006601 | 2022-09-15 | 2022-09-15 | Observation of curative effect of Du-moxibustion on patients with active ankylosing spondylitis | Clinical evaluation and mechanism study of moxibustion on Du meridian in the treatment of active ankylosing spondylitis | ankylosing spondylitis | healthy group:Oral celecoxib;therapy group:Du-Moxibustion (Moxibustion of Governor Vessel); | Affiliated Hospital of Shandong University of Traditional Chinese Medicine | NULL | Recruiting | 18 | 60 | Both | healthy group:30;therapy group:30; | China | |
| 2 | ChiCTR2100052323 | 2021-10-28 | 2021-10-24 | The treatment of Ankylosin Spondylitis by Bushenqiangduqinghuatang: A randomized controlled clinical trial | The treatment of Ankylosin Spondylitis by Bushenqiangduqinghuatang: A randomized controlled clinical trial | ankylosing spondylitis | treatment group:Bushenqiangduqinghuatang and celecoxib;Control group :celecoxib; | China-Japan Friendship Hospital | NULL | Recruiting | 16 | ? | Both | treatment group:41;Control group :41; | China | |
| 3 | ITMCTR2100004572 | 2021-03-09 | 2021-03-14 | Study on the effect of ginger with different thickness on the treatment of ankylosing spondylitis | Effect of Fuyang and Dumoxibustion on Ankylosing Spondylitis of Kidney-Yang Deficiency and on TNF-a and IL-6 | Ankylosing spondylitis | Thick ginger du moxibustion group:Oral celecoxib 20mg once a day, combined with Du moxibustion (ginger 5cm thickness);The control group:Celecoxib 20mg once daily;Ginger tube moxibustion group:Oral celecoxib 20mg once a day, combined with Du moxibustion (ginger thickness 3cm); | Affiliated Hospital of Nanjing University of Chinese Medicine | NULL | Recruiting | 18 | 60 | Male | Thick ginger du moxibustion group:20;The control group:20;Ginger tube moxibustion group:20; | China | |
| 4 | ChiCTR2100044284 | 2021-03-09 | 2021-03-14 | Study on the effect of ginger with different thickness on the treatment of ankylosing spondylitis | Effect of Fuyang and Dumoxibustion on Ankylosing Spondylitis of Kidney-Yang Deficiency and on TNF-a and IL-6 | Ankylosing spondylitis | The control group:Celecoxib 20mg once daily;Ginger tube moxibustion group:Oral celecoxib 20mg once a day, combined with Du moxibustion (ginger thickness 3cm);Thick ginger du moxibustion group:Oral celecoxib 20mg once a day, combined with Du moxibustion (ginger 5cm thickness); | Affiliated Hospital of Nanjing University of Chinese Medicine | NULL | Recruiting | 18 | 60 | Male | The control group:20;Ginger tube moxibustion group:20;Thick ginger du moxibustion group:20; | China | |
| 5 | ITMCTR2100004334 | 2021-02-01 | 2021-01-28 | Clinical Study on the Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western Medicine | Clinical Study on the Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western Medicine | Ankylosing Spondylitis | integrated traditional Chinese and western medicine:Bushen-Qiangdu-Zhilv decoction and Celecoxib Capsules; | Guangdong Provincial Hospital of Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | integrated traditional Chinese and western medicine:27; | China | |
| 6 | ChiCTR2100042789 | 2021-02-01 | 2021-01-28 | Clinical Study on the Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western Medicine | Clinical Study on the Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western Medicine | Ankylosing Spondylitis | integrated traditional Chinese and western medicine:Bushen-Qiangdu-Zhilv decoction and Celecoxib Capsules; | Guangdong Provincial Hospital of Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | integrated traditional Chinese and western medicine:27; | China | |
| 7 | ChiCTR2000034142 | 2019-04-01 | 2020-06-26 | Study on TCM Syndrome Classification and Diagnosis and Treatment of Ankylosing Spondylitis by Metabolomics | Study on TCM Syndrome Classification and Diagnosis and Treatment of Ankylosing Spondylitis by Metabolomics | Ankylosing spondylitis | Experimental group:Take Chinese medicine preparation Wen-Shen Juan-Bi-Tang orally;Experimental group 2:Take Chinese medicine preparation modified Wen-Shen Juan-Bi-Tang orally;NSAID:Take celecoxib orally; | Jiangsu Province Hospital of TCM | NULL | Pending | 25 | 70 | Both | Experimental group:40;Experimental group 2:40;NSAID:40; | N/A | China |
| 8 | ITMCTR2000003433 | 2019-04-01 | 2020-06-26 | Study on TCM Syndrome Classification and Diagnosis and Treatment of Ankylosing Spondylitis by Metabolomics | Study on TCM Syndrome Classification and Diagnosis and Treatment of Ankylosing Spondylitis by Metabolomics | Ankylosing spondylitis | Experimental group:Take Chinese medicine preparation Wen-Shen Juan-Bi-Tang orally;Experimental group 2:Take Chinese medicine preparation modified Wen-Shen Juan-Bi-Tang orally;NSAID:Take celecoxib orally; | Jiangsu Province Hospital of TCM | NULL | Pending | 25 | 70 | Both | Experimental group:40;Experimental group 2:40;NSAID:40; | N/A | China |
| 9 | NCT03473665 (ClinicalTrials.gov) | March 1, 2018 | 13/3/2018 | Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis | Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study | Ankylosing Spondylitis;Axial Spondyloarthritis | Drug: Indomethacin;Drug: Diclofenac;Drug: Meloxicam;Drug: Celecoxib | Columbia University | NULL | Terminated | 18 Years | N/A | All | 9 | Phase 4 | United States |
| 10 | NCT02758782 (ClinicalTrials.gov) | September 2016 | 20/4/2016 | NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis | COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial | Ankylosing Spondylitis | Biological: Golimumab;Drug: Celecoxib | Charite University, Berlin, Germany | NULL | Completed | 18 Years | N/A | All | 156 | Phase 4 | Germany |
| 11 | NCT02638896 (ClinicalTrials.gov) | January 2016 | 20/12/2015 | Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis | Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: etanercept (Half-Dose);Drug: etanercept (Full-Dose);Drug: Sulfasalazine;Drug: Celecoxib | Zhixiang Huang | NULL | Not yet recruiting | 18 Years | 45 Years | Both | 100 | Phase 4 | NULL |
| 12 | NCT01934933 (ClinicalTrials.gov) | September 24, 2014 | 17/8/2013 | Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis | A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: celebrex;Drug: Enbrel;Drug: Enbrel plus Celebrex | Sun Yat-sen University | NULL | Completed | 18 Years | 65 Years | All | 150 | Phase 4 | China |
| 13 | NCT01709656 (ClinicalTrials.gov) | March 2012 | 10/10/2012 | A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis | A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis | Ankylosing Spondylitis | Biological: MSC;Drug: celecoxib, Celebrex® | Sun Yat-sen University | NULL | Completed | 16 Years | 65 Years | Both | 120 | N/A | China |
| 14 | NCT00762463 (ClinicalTrials.gov) | July 2009 | 29/9/2008 | Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis | A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy | Ankylosing Spondylitis | Drug: Celecoxib;Drug: Diclofenac SR | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | NULL | Completed | 18 Years | 65 Years | All | 240 | Phase 3 | China |
| 15 | NCT00648141 (ClinicalTrials.gov) | January 2003 | 28/3/2008 | Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis | A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis | Spondylitis, Ankylosing | Drug: Celecoxib;Drug: Diclofenac | Pfizer | NULL | Completed | 18 Years | 75 Years | Both | 458 | Phase 3 | Germany |
| 16 | NCT02528201 (ClinicalTrials.gov) | September 2002 | 18/6/2015 | A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis | A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis | Ankylosing Spondylitis | Drug: Celecoxib 200 milligrams;Drug: Celecoxib 400 milligrams;Drug: diclofenac 50 milligrams | Pfizer | NULL | Completed | 18 Years | 75 Years | Both | 330 | Phase 4 | Norway |